The role of IGF-binding proteins in mediating the effects of recombinant human IGF-I on insulin requirements in type 1 diabetes mellitus.

To determine the role of IGF-binding proteins in mediating the direct effects of recombinant human IGF-I on insulin requirements in type 1(insulin-dependent) diabetes mellitus, overnight changes in IGF-I, IGF-II, and IGF-binding protein-1, -2, and -3, collected under euglycemic conditions, were compared in nine subjects after double blind, randomized, sc administration of recombinant human IGF-I (40 microg/kg) or placebo at 1800 h. On both nights a somatostatin analog infusion (300 ng/kg x h) suppressed endogenous GH production, and three timed discrete GH pulses (total, 0.029 IU/kg x night) ensured identical GH levels. After recombinant human IGF-I administration, IGF-I levels and the IGF-I/IGF-binding protein-3 ratio increased [mean +/- SEM:IGF-I, 401 +/- 22 ng/ml; placebo, 256 +/- 20 ng/ml (P = 0.0002); IGF-I, 0.108 +/- 0.006; placebo, 0.074 +/- 0.004 (P = 0.0003), respectively], and insulin requirements decreased (IGF-I, 0.12 +/- 0.03; placebo, 0.23 +/- 0.03 U/kg x min; P = 0.008). The normal within-individual inverse relationships between insulin and IGF-binding protein-1 levels were observed (lag time 2 h: r = -0.34; P < 0.01). Yet despite reduced free insulin levels (8.5 +/- 1.5; placebo, 12.2 +/- 1.2 mU/liter; P = 0.03), IGF-binding protein-1 levels were reduced after recombinant human IGF-I administration (53.7 +/- 6.8; placebo, 82.2 +/- 11.8 ng/ml; P = 0.008). The largest reductions in free insulin levels after recombinant human IGF-I and thus putative improvement in insulin sensitivity occurred in subjects with the smallest increase in the plasma IGF-I/IGF-binding protein-3 ratio (r = 0.7; P = 0.03). Taken together, these data are consistent with the hypothesis that transcapillary movement of IGF-I (perhaps mediated by IGF-binding protein-1), out of the circulation facilitates altered insulin sensitivity. These data have important implications for risk-benefit assessment of recombinant human IGF-I therapy in type 1 diabetes mellitus.

[1]  T. Quattrin,et al.  Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM Study Group. , 1999, Diabetes care.

[2]  D. Dunger,et al.  Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus. , 1998, Metabolism: clinical and experimental.

[3]  D. Dunger,et al.  Recombinant human insulin-like growth factor-I abolishes changes in insulin requirements consequent upon growth hormone pulsatility in young adults with type I diabetes mellitus. , 1998, Metabolism: clinical and experimental.

[4]  D. Dunger,et al.  Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus , 1997, The Lancet.

[5]  T. Quattrin,et al.  Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system. , 1997, The Journal of clinical endocrinology and metabolism.

[6]  T. Quattrin,et al.  Dual Hormonal Replacement With Insulin and Recombinant Human Insulin-Like Growth Factor I in IDDM: Effects on glycemic control, IGF-I levels, and safety profile , 1997, Diabetes Care.

[7]  C. Lang,et al.  Insulin-like growth factor-binding protein-2 and insulin: studies in children with type 1 diabetes mellitus and maturity-onset diabetes of the young. , 1995, The Journal of clinical endocrinology and metabolism.

[8]  M. Savage,et al.  The ‘dawn phenomenon’ in adolescents with insulin dependent diabetes mellitus: possible contribution of insulin‐like growth factor binding protein‐1 , 1995, Clinical endocrinology.

[9]  D. Dunger,et al.  The Effects of Repeated Daily Recombinant Human Insulin‐like Growth Factor I Administration in Adolescents with Type 1 Diabetes , 1995, Diabetic medicine : a journal of the British Diabetic Association.

[10]  D. Ishii,et al.  Insulin‐like growth factors protect against diabetic neuropathy: Effects on sensory nerve regeneration in rats , 1995, Journal of neuroscience research.

[11]  C. Bondy,et al.  The effects of subcutaneous insulin-like growth factor-I infusion in insulin-dependent diabetes mellitus. , 1994, The Journal of clinical endocrinology and metabolism.

[12]  D. Dunger,et al.  The effects of recombinant human insulin-like growth factor-I (IGF-I) administration on the levels of IGF-I, IGF-II and IGF-binding proteins in adolescents with insulin-dependent diabetes mellitus. , 1994, The Journal of endocrinology.

[13]  M. Phillip,et al.  Differential accumulation of insulin-like growth factor-I in kidneys of pre- and postpubertal streptozotocin-diabetic rats. , 1994, Journal of molecular endocrinology.

[14]  D. Dunger,et al.  The effects of recombinant human insulin‐like growth factor I on growth hormone secretion in adolescents with insulin dependent diabetes mellitus , 1994, Clinical endocrinology.

[15]  R. Menon,et al.  Insulin Therapy Increases Low Plasma Growth Hormone Binding Protein in Children with New‐onset Type 1 Diabetes , 1993, Diabetic medicine : a journal of the British Diabetic Association.

[16]  T. Nam,et al.  Use of insulin-like growth factor-binding protein-2 (IGFBP-2), IGFBP-3, and IGF-I for assessing growth hormone status in short children. , 1993, The Journal of clinical endocrinology and metabolism.

[17]  R. Baxter,et al.  Responses of insulin-like growth factor binding protein-1 (IGFBP-1) and the IGFBP-3 complex to administration of insulin-like growth factor-I. , 1993, Acta endocrinologica.

[18]  A. Dawson,et al.  Effects of CoA and acyl-CoAs on GTP-dependent Ca2+ release and vesicle fusion in rat liver microsomal vesicles. , 1993, The Biochemical journal.

[19]  D. Dunger,et al.  The frequency and amplitude of growth hormone secretory episodes as determined by deconvolution analysis are increased in adolescents with insulin dependent diabetes mellitus and are unaffected by short‐term euglycaemia , 1993, Clinical endocrinology.

[20]  D. Clemmons,et al.  Determination of the pharmacokinetic profiles of insulin-like growth factor binding proteins-1 and -2 in rats. , 1992, Endocrinology.

[21]  D. Dunger,et al.  The effect of insulin-like growth factor II on glucose uptake and metabolism in rat skeletal muscle in vitro. , 1992, The Biochemical journal.

[22]  J. Zierath,et al.  Insulin‐like growth factor II stimulates glucose transport in human skeletal muscle , 1992, FEBS letters.

[23]  D. Dunger,et al.  Diabetes in puberty. , 1992, Archives of disease in childhood.

[24]  R. Baxter,et al.  Abnormal regulation of insulin-like growth factor binding proteins in adolescents with insulin-dependent diabetes. , 1991, The Journal of clinical endocrinology and metabolism.

[25]  G. Cooney,et al.  Insulin-like growth factor-binding protein-1 modulates blood glucose levels. , 1991, Endocrinology.

[26]  R. Baxter,et al.  Insulin-like growth factor-binding protein-1: A role in glucose counterregulation? , 1991, Molecular and Cellular Endocrinology.

[27]  G. Braunstein,et al.  Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly. , 1991, The Journal of clinical endocrinology and metabolism.

[28]  D. Dunger,et al.  Increased overnight growth hormone concentrations in diabetic compared with normal adolescents. , 1990, Journal of Clinical Endocrinology and Metabolism.

[29]  M. Binoux,et al.  Regulation of binding proteins for insulin-like growth factors (IGF) in humans. Increased expression of IGF binding protein 2 during IGF I treatment of healthy adults and in patients with extrapancreatic tumor hypoglycemia. , 1990, The Journal of clinical investigation.

[30]  M. Boes,et al.  Insulin differentially alters transcapillary movement of intravascular IGFBP-1, IGFBP-2 and endothelial cell IGF-binding proteins in the rat heart. , 1990, Endocrinology.

[31]  D. Dunger,et al.  An Unbiased Glucose Clamp Method Using a Variable Insulin Infusion: Its Application in Diabetic Adolescents , 1990, Diabetic medicine : a journal of the British Diabetic Association.

[32]  D. Clemmons,et al.  Insulin-like growth factor-I (IGF-I) infusion into hypophysectomized or protein-deprived rats induces specific IGF-binding proteins in serum. , 1989, Endocrinology.

[33]  R. Baxter,et al.  Regulation of growth hormone-independent insulin-like growth factor-binding protein (BP-28) in cultured human fetal liver explants. , 1989, The Journal of clinical endocrinology and metabolism.

[34]  E. Froesch,et al.  Recombinant human insulin-like growth factor I induces its own specific carrier protein in hypophysectomized and diabetic rats. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Dunger,et al.  Somatomedin-C/IGF-I measured by radioimmunoassay and somatomedin bioactivity in adolescents with insulin dependent diabetes compared with puberty matched controls. , 1988, Diabetes research.

[36]  T. Chard,et al.  ORCADIAN VARIATION OF GH‐INDEPENDENT IGF‐BINDING PROTEIN IN DIABETES MELLITUS AND ITS RELATIONSHIP TO INSULIN. A NEW ROLE FOR INSULIN? , 1988, Clinical endocrinology.

[37]  M. Grant,et al.  Insulin-Like Growth Factors in Vitreous: Studies in Control and Diabetic Subjects with Neovascularization , 1986, Diabetes.

[38]  H. Keen.  Normoglycaemic Re‐entry and Diabetic Complications , 1984, Diabetic medicine : a journal of the British Diabetic Association.

[39]  E. Froesch,et al.  Insulin-like growth factors. Studies in diabetics with and without retinopathy. , 1983, The New England journal of medicine.